Ahmed M Aref et al. showed that targeting TPX2 with specific peptides was able to improve the efficacy of cytotoxic T lymphocytes (CTLs) in T cell-mediated HCC immunotherapy [38]. Here, TPX2 is linked to hepatocellular carcinoma.